Objective: Temporal lobe epilepsy (TLE) accompanied by hippocampal sclerosis (HS) is the most common type of focal epilepsies. Hemispheric asymmetry is a feature of brain organization in both invertebrates and vertebrates and may be the key to some neurodegenerative diseases. In this context, we aimed to investigate the volumetric asymmetry difference in cerebral structures between TLE patients and the healthy control group, based on magnetic resonance imaging (MRI) data that may be used as a new neuroimaging marker for TLE cases. Patients and Methods: In this retrospective study the cranial MRIs of fourteen clinically manifesting, radiologically HS-identified, and diagnosed TLE patients and fourteen healthy individuals from the Radiology Department of Yeditepe University Hospital were evaluated. Volume measurements and asymmetry index (AI) calculations in the total brain, hippocampus, temporal lobe, amygdala, thalamus, nucleus accumbens (NAc), premotor cortex, primary and somatosensory cortices were performed using the medical NeuroQuant® software. A negative AI value represented asymmetry towards the right due to reduced left hemispheric volume; a positive AI value represented asymmetry towards the left due to reduced right hemispheric volume. Subsequently, differences in volume and asymmetric patterns were investigated among TLE subgroups (right and left-sided TLE) and controls. Results: The left-sided TLE patients showed significant bilateral total brain volume reduction compared to the control group. Significant ipsilateral volumetric declines were also detected in the premotor cortex, the temporal lobe, and NAc with remarkable asymmetry to the right side. No significant changes were detected in right-sided TLE patients compared to the other groups. Conclusion: Overall, findings suggest that TLE patients had volumetric alterations with symmetry changes beyond the mesial temporal structures. With further investigations, the asymmetry measures can provide additional knowledge for TLE diagnosis.
Objective: This study investigates the diagnostic potential of fractional anisotropy (FA), derived from diffusion tensor imaging (DTI),for distinguishing low-grade (grade 1–2) from high-grade (grade 3–4) gliomas by evaluating the tumor core, tumor margin, andperitumoral region.Patients and Methods: Sixty patients with histopathologically confirmed gliomas (grade 1–2, n=30; grade 3–4, n=30) underwentpreoperative 3T Magnetic Resonance Imaging (MRI) including DTI. FA was measured in the tumor core (solid component), tumormargin, peritumoral region, and contralateral normal-appearing white matter (NAWM). NAWM-normalized FA ratios were alsoevaluated. Groups were compared using independent-samples t tests, and diagnostic performance was evaluated with receiveroperating characteristic (ROC) analysis including AUC, optimal cut-off, sensitivity, and specificity.Results: Fractional anisotropy in tumor-related regions was lower than contralateral NAWM in both groups. Grade 3–4 gliomasshowed significantly lower raw FA in the tumor core, tumor margin, and peritumoral region, whereas NAWM FA did not differbetween groups. NAWM-normalized FA ratios were also significantly reduced in grade 3–4 gliomas (all p < 0.05). Tumor core raw FAshowed the highest discrimination (AUC = 0.842, 95% CI: 0.734–0.932, cut-off = 0.150, sensitivity = 0.80, specificity = 0.73).Conclusion: Raw and NAWM-normalized FA metrics, particularly in the tumor core and peritumoral region, differentiated grade 1–2from grade 3–4 gliomas and may serve as supportive noninvasive markers for preoperative grading.
26 March 2026 in Turkish Journal of Intensive Care
Paroxysmal sympathetic hyperactivity syndrome (PSH) is a rarely diagnosed syndrome associated with acute brain injury which involves traumatic brain injury, stroke, infectious diseases, and encephalopathy, and results in cyclic episodes of sympathetic and motor hyperactivity (hypertension, tachypnea, hyperthermia, diaphoresis, dystonic posturing). Even though there are some theories regarding the pathophysiology of PSH, the main mechanism still remains unclear. However, it is mostly agreed upon that PSH is caused by an unbalanced activation of the autonomic nervous system caused by the loss of inhibition of excitation in the sympathetic nervous system. Although PSH has been well known for many decades there were misunderstandings regarding the nomenclature and the definition of this syndrome. The term “Paroxysmal Sympathetic Hyperactivity and a diagnostic tool consisted of two different components and named PSH-Assessment Measure (PSH-AM),” was developed to help guiding clinical management in 2014. These components are the diagnostic likelihood tool and the clinical features scale. To diagnose this syndrome first other neurological issues should be ruled out. Once diagnosed in order to treat and avoid secondary brain damage and other adverse outcomes of this syndrome an approach of both pharmacological (such as opioids, B-blockers, alfa2 agonists, benzodiazepines, gabapentin and muscle relaxants) and nonpharmacological should be combined. Pharmacological approach focuses on symptom abortion, prevention and refractory treatment.